We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Carisma Therapeutics Inc | NASDAQ:CARM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -5.26% | 1.08 | 1.08 | 1.20 | 1.14 | 1.07 | 1.12 | 113,157 | 23:56:56 |
Thursday 25 July 2024
Regulatory News:
Carmila (Paris:CARM) has made available to the public and filed with the French financial markets authority (Autorité des Marchés Financiers) its 2024 Half Year Financial Report.
It can be consulted on Carmila’s website www.carmila.com, in the Finance section.
INVESTOR AGENDA 25 July 2024: First half 2024 results presentation 17 October 2024 (after market close): Financial information for the third quarter 2024
ABOUT CARMILA
As the third-largest listed owner of commercial property in Europe, Carmila was founded by Carrefour and large institutional investors in order to enhance the value of shopping centres adjoining Carrefour hypermarkets in France, Spain and Italy. At 31 December 2023, its portfolio was valued at €5.9 billion and is made up of 201 shopping centres, with leading positions in their catchment areas.
Carmila is listed on Euronext-Paris Compartment A under the symbol CARM. It benefits from the tax regime for French real estate investment trusts (“SIIC”). Carmila has been a member of the SBF 120 since 20 June 2022.
This press release is available in the “Financial Press Releases” section of Carmila’s Finance webpage: https://www.carmila.com/en/finance/financial-press-releases
Visit our website at https://www.carmila.com/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724455400/en/
INVESTOR AND ANALYST CONTACT Pierre-Yves Thirion - CFO pierre_yves_thirion@carmila.com +33 6 47 21 60 49 PRESS CONTACT Elodie Arcayna – Directrice communication elodie_arcayna@carmila.com +33 7 86 54 40 10
1 Year Carisma Therapeutics Chart |
1 Month Carisma Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
